Abeona Therapeutics Inc. · NASDAQ:ABEO
Abeona Therapeutics — Q1 2026 Earnings Presentation
21 slides from Abeona Therapeutics's earnings presentation, May 13, 2026
Slide 1: Corporate Overview
Sig beona’ Corporate Overview
Slide 2: Note regarding forward-looking statements
Note regarding forward-looking s tatements This presentation of Abeona Therapeutics Inc. (the “Company”) contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amende
Slide 3: Abeona is poised for growth with ZEVASKYN commercial launch
Abeona is pois ed for growth with ZEVASKYN commercial launch Significant interest in ZEVASKYN from the RDEB community • ZEVASKYN now available at multiple qualified treatment centers (QTCs); additional QTC activations ongoing • Identified eligible patients is growing across QTCs and referring HCPs a
Slide 4: RDEB is caused by the lack of functional C7 protein
RDEB is caus ed by the lack of functional C7 protein, which res ults in the development of large, chronic wounds Healthy skin cells RDEB skin cells VS • Type VII collagen (C7) helps form anchoring fibrils, structures that bond the epidermis to dermis • COL7A1 gene mutations and the resulting lack of
Slide 5: RDEB significantly minimizes length and quality of life
RDEB significantly minimizes length and quality of life • >30% of patient’s body wounded • Large, painful chronic wounds; risk of infection Clinical • 90% risk of developing SCC by age 55 • 76% likelihood of death by age 40 • High HCRU, ongoing economic burden (up to $15M potential lifetime cost) as
Slide 6: First and only gene therapy made from patient's own skin cells to treat wounds
First and only gene therapy made from patient's own skin cells to treat wounds in children & adults with RDEB • Single treatment application • Covers large wound areas • Provides years of healing & pain relief Geovanna, a ZEVASKYN patient at age 8 6
Slide 7: Up to 12 ZEVASKYN sheets can be applied in one surgical session
Up to 12 ZEVASKYN s heets can be applied in one s urgical s es s ion ZEVASKYN sheets can be joined together to treat Two 0.8 cm up to 12 larger wounds on your front, back, or sides, or used punch biopsies ZEVASKYN sheets individually for smaller wounds up to 12 ZEVASKYN sheets ZEVASKYN cellular shee
Slide 8: Example RDEB wounds before & after ZEVASKYN treatment
Example RDEB wounds before & after ZEVASKYN treatment Source: Phase 3 VIITAL study patient; wounds scored as at least75% healing at week24; individual results vary 8 Wound healing scoring was Investigator-assessed per predefinedcriteria.
Slide 9: Phase 3 VIITAL study clinical experience
Phas e 3 VIITAL s tudy clinical experience 1 Wound healing and pain reduction with a single surgical application – even in tough RDEB wounds • 81% (35/43) of treated wounds achieved 50% or more • Wounds assessed at baseline had been open for a healing vs 16% (7/43) of controls at week 24 median of 5
Slide 10: Example of multi-year wound healing after single ZEVASKYN application
Example of multi-year wound healing after s ingle ZEVASKYN application • Separate study of 7 patients with RDEB (38 chronic wounds) • Patients followed for a median of 6.9 years (range 4-8 years), with planned follow-up of 15 years*† • Study did not evaluate treated wounds vs control wounds or place
Slide 11: Collagen VII protein expression observed for 24 months at ZEVASKYN treated site
Collagen VII protein expres s ion obs erved for 24 months at ZEVASKYN treated s ite No anchoring fibrils Anchoring fibril expression after treatment Baseline 3 months Year 1 Year 2 No collagen VII expression Collagen VII expression after treatment Baseline 3 months Year 1 Year 2 Phase 1/2a study pat
Slide 12: ZEVASKYN patient journey
ZEVASKYN patient journey ZEVASKYN Hospital stay & Patient Biopsy sample ZEVASKYN surgical discharge intake procurement manufacturing procedure 1 2 3 4 5 • Prior authorization • Site reimbursement agreement • Scheduling biopsy 12
Slide 13: Strong Together Network of ZEVASKYN patients and caregivers
“I am very happy. “The benefit is I saw “It was the first time I “My kids know it was a “I still would definitely “I think that the thing This trial changed healing, compared to saw pink skin. life altering moment, do it again. It gets so that people don't my life completely.” other treatment, Beaut
Slide 14: EB patients already travel significant distances for specialized care
EB patients already travel s ignificant dis tances for s pecialized care and have indicated willingnes s to travel for ZEVASKYN Referral Catchment Areas For Key EB COEs (2022-2023) 50 mi. 300 mi. 50 mi. Patient support hub 500 mi. 100 mi. Personalized support when you need it (1-855-ABEONA-1) Catchm
Slide 15: ZEVASKYN may only be administered at a Qualified Treatment Center
ZEVASKYN may only be adminis tered at a Qualified Treatment Center Currently available at 5 QTC’s Ann & Robert H. Lurie Children's Hospital of Chicago NewYork-Presbyterian/ Stanford Medicine Children's Hospital Columbia University Children's Health Colorado Irving Medical Center The University of Te
Slide 16: Significant US commercial opportunity for ZEVASKYN
Significant US commercial opportunity for ZEVASKYN ~1,300 US DEB patients1; ~750 RDEB ZEVASKYN-eligible patients Anticipate average 2 treatment cycles per patient to cover impacted body areas (~1500 treatment opportunities) $3.1M WAC per each treatment; >$4B cumulative revenue opportunity in the US
Slide 17: Strong payer coverage and reimbursement
Strong payer coverage and reimburs ement Payer engagement continues to reinforce awareness Positive coverage for ZEVASKYN established with multiple Medicare, large national and regional payers 10% To date, 100% of submitted prior authorization requests Medicaid, have been approved 30% Commercial, 60
Slide 18: Commercial manufacturing for ZEVASKYN
Commercial manufacturing for ZEVASKYN GMP Commitment Near Term Ramp-Up Long Term Expansion Annual maintenance of equipment Supply ramp-up at current GMP Production capacity expansion and facility for quality assurance facility to match projected for ZEVASKYN growth and compliance initial demand 18
Slide 19: Focused on delivering exceptional ZEVASKYN treatment experience
Focus ed on delivering exceptional ZEVASKYN treatment experience Patient support hub Patient-to-patient Learn more about communication and ZEVASKYN engagement Personalized support when you need it Talk to ZEVASKYN patients and (1-855-ABEONA-1) caregivers about their experience Abeona Assist Strong T
Slide 20: Pipeline of differentiated cell and gene therapies
Pipeline of differentiated cell and gene therapies PRECLINICAL PHASE 1/2 PHASE 3 APPROVED ABO-503 X-linked retinoschisis (XLRS) ABO-504 Stargardt disease ABO-505 Autosomal dominant optic atrophy (ADOA) UX111* PARTNERED Sanfilippo syndrome type A (MPS IIIA) TSHA-102** Rett syndrome 20 Partnered with
Slide 21: Summary
Summary • Significant interest in ZEVASKYN from the RDEB community • ZEVASKYN commercial launch underway with multiple qualified treatment centers activated, and more activations ongoing • $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 • Monthly profitability up